Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
NEW YORK, Sept. 13, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. (“Emergent Biosolutions” or the “Company”) (NYSE:EBS) between January 11, 2016 and June 21, 2016.
You are hereby notified that a class action has been commenced in the USDC for the District of Maryland. If you purchased or otherwise acquired Emergent Biosolutions securities between January 11, 2016 and June 21, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/emergent-biosolutions
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that defendants issued materially false and misleading information regarding the Company’s business and financial prospects, particularly in relation to potential contract renewals and demand from the U.S. government for its anthrax vaccine BioThrax. The complaint further alleges that these positive statements caused the stock to trade at artificially inflated prices, allowing insiders to sell their shares at these inflated prices.
On June 22, 2016, before the open of trading, Emergent Biosolutions announced that the U.S. government had notified the Company it would only be purchasing 29.4 million doses of the vaccine over the following five years—an amount approximately one third less than the original contract. In addition, the Company disclosed that the government was seeking other anthrax vaccines, and that it was putting its supply bid out to other companies.
If you suffered a loss in Emergent Biosolutions you have until September 19, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
